Table 3.

Outcome at 18 months’ follow-up

Value	Estimate	95% CI	P-value	P-value for interactiona
Difference in mean NYHA
Non-IHD	−0.53	−0.74 to −0.33	<0.0001	0.30
IHD	−0.69	−0.69	<0.0001
End of study status (odds ratio)
Non-IHD	0.52	0.35 to 0.76	0.0009	0.49
IHD	0.42	0.27 to 0.66	0.0001
Difference in mean MR
Non-IHD	4.77	1.12 to 8.42	0.0109	0.83
IHD	4.16	−0.44 to 8.75	0.0755
LVEF (%)
Non-IHD	8.50	10.14 to 6.85	<0.0001	0.003
IHD	4.53	6.24 to 2.82	<0.0001
LVESV (cm3)
Non-IHD	−58.52	45.56 to 71.49	<0.0001	0.01
IHD	−35.68	20.80 to 50.56	<0.0001
NT-proBNP
Non-IHD	−1231.24	−1992.53 to −469.96	0.0016	0.97
IHD	−1137.89	−2441.17 to 165.38	0.0866
Difference in mean QRS
Non-IHD	−19.8	−25.5 to −14.1	<0.0001	0.03
IHD	−9.7	−16.4 to −2.9	0.0052

IHD, ischaemic heart disease; MLWHF, Minnesota living with heart failure questionnaire; MR, mitral regurgitation.

^aBetween effect of treatment and ischaemia.